ABXY 2
Alternative Names: ABXY-2Latest Information Update: 01 Nov 2022
At a glance
- Originator Abaxys Therapeutics
- Class Small molecules
- Mechanism of Action Ubiquitin-specific protease modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurological disorders
Most Recent Events
- 01 Nov 2022 Early research in Neurological disorders in Belgium (unspecified route) before November 2022 (Abaxys Therapeutics pipeline, November 2022)